Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review
ConclusionsOutcomes for DMG-SCs are poor overall but appear to be favorable compared to intracranial DMGs. Despite the recent WHO 2021 grade 4 classification for all DMGs, given the differences in overall survival reported based on historical grading systems, future studies on DMG-SCs are needed to further define if DMG-SCs may represent a heterogeneous group of tumors with different prognoses. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 12, 2024 Category: Cancer & Oncology Source Type: research
AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway
Glioblastoma (GBM) is the most common brain tumor with the worst prognosis. Temozolomide is the only first-line drug for GBM. Unfortunately, the resistance issue is a classic problem. Therefore, it is essentia... (Source: Cancer Cell International)
Source: Cancer Cell International - February 10, 2024 Category: Cancer & Oncology Authors: Yizhi Zhang, Wan Li, Yihui Yang, Sen Zhang, Hong Yang, Yue Hao, Xu Fang, Guanhua Du, Jianyou Shi, Lianqiu Wu and Jinhua Wang Tags: Research Source Type: research
Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells-derived exosomes
CONCLUSION: The present study illustrated a new mechanism of glioblastoma resistance to TMZ, which based on GSCs-exo educated TAAs delivering ALKBH7 to enhance APNG expression of GBM cells, which implied that targeting on ALKBH7/APNG regulation network may provide a new strategy of enhancing TMZ therapeutic effects against glioblastoma.PMID:38332576 | PMC:PMC10853646 | DOI:10.1111/cns.14599 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - February 9, 2024 Category: Neuroscience Authors: Xinglei Liu Liang Liu Anyi Wu Shilu Huang Zhipeng Xu Xiaopei Zhang Zengyang Li Haoran Li Jun Dong Source Type: research
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy
Despite significant advances in our knowledge regarding the genetics and molecular biology of gliomas over the past two decades and hundreds of clinical trials, no effective therapeutic approach has been identified for adult patients with newly diagnosed glioblastoma, and overall survival remains dismal. Great hopes are now placed on combination immunotherapy. In clinical trials, immunotherapeutics are generally tested after standard therapy (radiation, temozolomide, and steroid dexamethasone) or concurrently with temozolomide and/or steroids. Only a minor subset of patients with progressive/recurrent glioblastoma have ben...
Source: Frontiers in Immunology - February 8, 2024 Category: Allergy & Immunology Source Type: research
Exposure of human glioblastoma cells to thimerosal inhibits the thioredoxin system and decreases tumor growth-related factors
The objective of this study was to verify whether thimerosal is a suitable candidate for hard repurposing to control glioblastoma; therefore, the effects of this molecule were evaluated in human GBM (U87) cells. Our novel results show that TmHg decreased cellular viability (>50%) and migration (up to 90% decrease in wound closure), reduced thioredoxin reductase (TrxR/TXNRD1) and thioredoxin (Trx) activity, and increased reactive oxygen species (ROS) generation. Moreover, TmHg reduced HIF-1α expression (35%) as observed by immunofluorescence. Co-exposure of U87 cells to TmHg and TMZ reduced HIF-1α, VEGF, and phosphoryl...
Source: Toxicology and Applied Pharmacology - February 7, 2024 Category: Toxicology Authors: Isabella Bramatti Michael Aschner Vasco Branco Cristina Carvalho Source Type: research
Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions
Cellular therapies, including chimeric antigen receptor T cell therapies (CAR-T), while generally successful in hematologic malignancies, face substantial challenges against solid tumors such as glioblastoma (GBM) due to rapid growth, antigen heterogeneity, and inadequate depth of response to cytoreductive and immune therapies, We have previously shown that GBM constitutively express stress associated NKG2D ligands (NKG2DL) recognized by gamma delta (γδ) T cells, a minor lymphocyte subset that innately recognize target molecules via the γδ T cell receptor (TCR), NKG2D, and multiple other mechanisms. Given that NKG2DL e...
Source: Frontiers in Immunology - February 7, 2024 Category: Allergy & Immunology Source Type: research
Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy
Biomaterials. 2024 Jan 20;306:122479. doi: 10.1016/j.biomaterials.2024.122479. Online ahead of print.ABSTRACTDue to glioblastoma (GBM) being the most intractable brain tumor, the continuous improvement of effective treatment methods is indispensable. The combination of siRNA-based gene therapy and chemotherapy for GBM treatment has now manifested great promise. Herein, Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles (MSN) encapsulating chemotherapy drug temozolomide (TMZ), termed as TMSN@siHDGF-Gint4.T, is developed to co-deliver gene-drug siHDGF and TMZ for synergistic GBM therapy. TMSN@siHDGF-Gint4.T posses...
Source: Biomaterials - January 31, 2024 Category: Materials Science Authors: Huaijun Fei Yang Jin Nan Jiang Yuhan Zhou Ningcheng Wei Yifan Liu Jiayi Miao Liying Zhang Rui Li Aixia Zhang Shuhu Du Source Type: research
Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells
The methylation status of the O6-methylguanine DNA methyltransferase (MGMT) promoter region is a critical predictor of response to alkylating agents in glioblastoma. However, current approaches to study the MGMT status focus on analyzing models with non-identical backgrounds. Here, we present an epigenetic editing approach using CRISPRoff to introduce site-specific CpG methylation in the MGMT promoter region of glioma cell lines. Sanger sequencing revealed successful introduction of methylation, effectively generating differently methylated glioma cell lines with an isogenic background. The introduced methylation resulted ...
Source: Frontiers in Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
ConclusionPreoperative Bev and TMZ is safe as long as the instructions are followed. The strategy might be useful for GB in some patients, not only reducing tumor burden, but also improving patient KPS preoperatively.Trial Registration Number: UMIN000025579, jRCT1031180233https://jrct.niph.go.jp/latest-detail/jRCT1031180233. Registration Date: Jan. 16, 2017 (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment
ConclusionThese results indicate GPR68 emerges as a critical sensor for an autocrine pro-tumorigenic signaling cascade triggered by extracellular acidification in glioblastoma cells. In this context, GPR68 suppresses ATF4, inhibition of GPR68 increases expression of ATF4 which leads to ferroptotic cell death. These findings provide a promising therapeutic approach to selectively induce ferroptosis in glioblastoma cells while sparing healthy neural tissue. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 30, 2024 Category: Cancer & Oncology Source Type: research
